Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT;Quantifizierung der Somatostatinrezeptorexpression neuroendokriner Tumoren mit der 68Ga-DOTATATE-PET/CT

Radiologe

Volumn 50, Issue 4, 2010, Pages 349-354

  Haug, A R ^a   Assmann, G ^a   Rist, C ^a   Tiling, R ^a   Schmidt, G P ^a   Bartenstein, P ^a   Hacker, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Gallium 68 (68Ga); Neuroendocrine tumors (NET); Positron emission tomography (PET); Somatostatin receptor (SSTR); Standardized uptake value (SUV)

Indexed keywords

68GA DOTATATE; 68GA-DOTATATE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ADULT; AGED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77952675021     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-009-1972-2     Document Type: Article

References (21)

1. Asnacios A, Courbon F, Rochaix P et al (2008) Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 26:963-970
2. Beuthien-Baumann B, Strumpf A, Zessin J et al (2007) Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34:1604-1609
3. Breeman WA, de Jong M, de Blois E et al (2005) Radiolabelling DOTA-peptides with 68 Ga. Eur J Nucl Med Mol Imaging 32:478-485
4. Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68-Ga-DOTATOC PET and 111-In-DTPAOC (octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617-1626
5. De Jong M, Kwekkeboom D, Valkema R, Krenning EP (2003) Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 30:463-469
6. Decristoforo C, Mather SJ, Cholewinski W et al (2000) 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 27:1318-1325
7. Gabriel M, Decristoforo C, Kendler D et al (2007) 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508-518
8. Garin E, Le Jeune F, Devillers A et al (2009) Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50:858-864
9. Hartmann H, Zophel K, Freudenberg R et al (2009) Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin 48:201-207
10. Haug A, Auernhammer CJ, Wangler B et al (2009) Intraindividual comparison of (68)Ga-DOTATATE and (18)F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36:765-770
11. Kauhanen S, Seppanen M, Minn H et al (2007) Fluorine-18-L- dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab 92:1237-1244
12. Kayani I, Bomanji JB, Groves A et al (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 112:2447-2455
13. Miederer M, Seidl S, Buck A et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36:48-52
14. Montravers F, Grahek D, Kerrou K et al (2006) Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 47:1455-1462
15. Papotti M, Bongiovanni M, Volante M et al (2002) Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461-475
16. Prasad V, Ambrosini V, Hommann M et al (2009) Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37:67-77
17. Ruf J, Heuck F, Schiefer J et al (2010) Impact of multiphase Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 91:101-109
18. Seemann MD (2007) Detection of metastases from gastrointestinal neuroendocrine tumors: prospective comparison of 18F-TOCA PET, triple-phase CT, and PET/CT. Technol Cancer Res Treat 6:213-220
19. Timmers HJ, Chen CC, Carrasquillo JA et al (2009) Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94:4757-4767
20. Volante M, Brizzi MP, Faggiano A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172-1182
21. Yao JC, Hassan M, Phan A et al (2008) One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072